标题：血浆D-二聚体检测在肝癌分期与预后中的临床价值

      作者：邓杰 1，阿不来提 2，朱兵 2，程林 1，买海木 1，黄志高 1
    (1.新疆生产建设兵团第三师图木舒克市人民医院检验科，新疆 图木舒克 843901)
2.新疆维吾尔自治区人民医院全科医疗科，新疆 乌鲁木齐 830001)

      卷次： 2016年27卷18期

      【摘要】 目的 检测肝癌患者血浆中的D-二聚体，探讨其在肝癌不同分期及预后治疗中的临床价值。
方法 采用免疫比浊法对 2012年 1月至 2014年 1月在新疆自治区人民医院就诊且资料完整的 50例肝癌患
者和 35例正常对照组血浆中D-二聚体含量进行检测，比较肝癌患者不同分期及治疗前后的D-二聚体水平
变化。结果 本组50例肝癌患者各临床期血浆D-二聚体检测含量为Ⅰ期(0.43±0.10) mg/L，Ⅱ期(0.60±0.14) mg/L，
Ⅲ期(1.65±0.32) mg/L，与正常对照组比较，肝癌患者血浆中D-二聚体含量均上升且随肿瘤分期逐步进展而升高，
差异均有统计学意义(P<0.05或P<0.01)；肝癌患者治疗后缓解组 40例，未缓解组 10例，治疗前D-二聚体含量为
(0.84±0.12) mg/L，治疗后缓解组D-二聚体含量为(0.50±0.21) mg/L，治疗后血浆中D-二聚体含量较治疗前明显降
低，差异有统计学意义(P<0.05)。结论 肝癌患者存在不同程度的继发性纤维蛋白溶解功能亢进，检测血浆中D-
二聚体含量可作为判断病情严重程度及治疗预后的参考指标。

      【关键词】 D-二聚体；肝癌；分期；预后

      【中图分类号】 R735.7 【文献标识码】 A 【文章编号】 1003—6350（2016）18—2937—03


Clinical significance of plasma D-dimer in patients with different liver cancer staging and prognosis.
DENG Jie 1, A
Bu-lai-ti 2, ZHU Bing 2, CHENG Lin 1, MAI Hai-mu 1, HUANG Zhi-gao 1. 1. Departmeat of Clinical Laboratory, the
People's Hospital of Tumshuq City, the Third Divisions of Xinjiang Production and Construction Corps, Tumshuq 843901,
Xinjiang, CHINA; 2. General Medical Department, the People's Hospital of Xinjiang Uigur Autonomous Region, Urumqi
830001, Xinjiang, CHINA

【Abstract】 Objective To detect the plasma D-dimer levels in patients with hepatocellular carcinoma
(HCC), and to investigate the clinical significance of D-dimer levels in different stages of HCC and the prognosis of
treatment. Methods By using immunoturbidimetric method, the plasma D-dimer levels were detected in 50 patients
with HCC and and 35 healthy controls from January 2012 to January 2014 in the People's Hospital of Xinjiang Uigur Au-
tonomous Region. The changes of D-dimer levels in different stages of HCC and before and after treatment were com-
pared. Results In HCC patients, the D-dimer level was (0.43±0.10) mg/L for periodⅠ, (0.60±0.14) mg/L for periodⅡ,
(1.65±0.32) mg/L for period Ⅲ. Compared with healthy controls, the plasma D-dimer levels in HCC patients were in-
creased, and the levels increased gradually with the progression of clinical tumor stage (P<0.05 or 0.01). In the 50 HCC
patients, 40 patients were alleviated after treatment and 10 patients were not alleviated. The plasma D-dimer level before
treatment was (0.84±0.12) mg/L, and the level was (0.50±0.21) mg/L in the alleviated group, with statistically significant
difference (P<0.05). Conclusion HCC patients have high condensation state and fibrinolytic hyperthyroidism of differ-
ent degree. The plasma D-dimer levels may serve as an important parameter for differentiation and evaluating the severi-
ty of the disease.

      【Key words】 D-dimer; Liver cancer; Staging; Prognosis
·论 著·
6350.2016.18.005